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Melina R. Kibbe, MD, Mark D. Morasch, MD, Heron E. Rodriguez, MD, and
William H. Pearce, MD, Chicago, Ill
Objectives: Vascular surgeons have increasingly become proficient in carotid artery stenting (CAS) as an alternative treatment
modality for cervical carotid artery occlusive disease. We analyzed our early and late outcomes of CAS over the last 8 years.
Methods: We report a single-center retrospective review of 388 carotid bifurcation lesions treated with CAS using cerebral
embolic protection from May 2001 to July 2009. Data analysis includes demographics, procedural records, duplex exams,
arteriograms, and two-view plain radiographs over a mean follow-up time of 23.0 months (interquartile range, 10.9-35.4).
Results:At the time of treatment, themean age of the entire cohort (76%men and24%women) is 71 years; 13%were>80 years
of age, and 31% had a prior history of either carotid endarterectomy (CEA) and/or external beamneck irradiation (XRT). The
mean carotid stenosis is 80%, and asymptomatic lesions represent 69% of the group. Overall 30-day rates of death, stroke, and
myocardial infarction are 0.5%, 1.8%, and 0.8%, respectively. The combined death/stroke rate at 30 days is 2.3%. The 30-day
major/minor stroke rates for analyzed subgroups are statistically significant only for XRT/recurrent stenosis vs de novo
lesions, 0% and 2.6% (P .03), but not for asymptomatic vs symptomatic patients, 1.9% and 1.7% (P .91) and age<80 vs
>80, 2.0% and 1.8% (P  .52), respectively. At long-term, the freedom from all strokes at 12, 24, 36, and 48 months was
99.2%, 97.6%, 96.7%, and 96.7%, respectively. At late follow-up, the restenosis rate is 3.5%. Restenosis rates for recurrent
stenosis/XRT vs de novo lesions are 2.7% and 3.4% (P .39). Among the restenotic lesions were two associated type III stent
fractures in de novo lesions, both ofwhichwere closed-cell stents. An additional two other type I fractures have been identified,
yielding a stent fracture rate of 5.5%. The late death rate for the entire group is 16.8%, with one stent-related death secondary
to ipsilateral stroke at 20 months (0.3% death rate).
Conclusions: Vascular surgeons performing CAS with embolic protection can achieve good early and late outcomes that
are comparable to CEA benchmarks. Late stent failures (stroke, restenosis, and/or stent fatigue), while uncommon, are
a recognized delayed problem. (J Vasc Surg 2010;51:1145-51.)Stroke prevention remains the primary objective of any
treatment for carotid bifurcation stenosis. While medical
therapy is at the cornerstone, several randomized trials
comparing surgery with optimal medical therapy have es-
tablished carotid endarterectomy (CEA) as the gold stan-
dard surgical option for treatment of extracranial carotid
artery occlusive disease in certain instances.1-5 Carotid ar-
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doi:10.1016/j.jvs.2009.12.025tery stenting (CAS) has emerged as a controversial alterna-
tive but awaits outcomes from notable large-scale random-
ized trials for final disposition.
Although excellent results from centers with a high-vol-
ume experience seem to demonstrate that CAS is technically
feasible and safe, given the limited number of randomized
controlled trials (RCTs) conducted thus far, there is an ongo-
ing debate over the equivalence of CAS compared with CEA
in terms of early and long-term outcomes in standard-risk
patients. Currently, the safety of CAS is being investigated in
both high-risk and standard-risk patients with the Carotid
Revascularization Endarterectomy versus Stenting Trial
(CREST) and the Asymptomatic Carotid stenosis stenting
versus endarterectomy Trial (ACT 1), among others.6,7
Another important consideration with CAS is the du-
rability of the procedure. Only a few nonrandomized stud-
ies have focused their attention on mid- and long-term
results. Long-term patency following CAS can be limited
by restenosis due to neointimal hyperplasia, recurrent ath-
erosclerosis, and stent fatigue. The purpose of this study
was to analyze our early and late outcomes of CAS over the
last 8 years at a single institution.
METHODS
Study design
The study protocol was approved by the human rights
committee of each local institutional review board. Data
1145
JOURNAL OF VASCULAR SURGERY
May 20101146 Eskandari et almanagement and statistical analyses were performed solely
by the department, whose members had full access to the
data and vouch for the accuracy and completeness of the
data and the analyses. The companies that provided finan-
cial support, products, or both had no role in the design,
analysis, or interpretation of the study. This study is a
retrospective review fromMay 2001 to July 2009 at North-
western Memorial Hospital and the Jesse Brown or Lake-
side Veteran Administration Medical Centers, in Chicago,
IL. These facilities perform a high volume of vascular and
interventional surgery cases and are located in an urban city
setting. All procedures were performed by board-certified
vascular surgeons with advanced endovascular skills. Data
analysis includes demographics, procedural records, duplex
exams, arteriograms, and two-view plain radiographs.
Study population
Carotid revascularization was performed on patients
presenting with either an asymptomatic carotid stenosis
80% or a symptomatic carotid stenosis50% as measured
by North American Symptomatic Carotid Endarterectomy
Trial (NASCET) on conventional angiography. Patients
were referred to CAS instead of CEA for a variety of
reasons, including anatomical CEA inaccessibility, prior
XRT, restenosis, octogenarian, surgical comorbidity, or if
patients were enrolled in a randomized control trial or
registry.
All procedures were performed in an operating room
angiosuite with either a fixed (V5000; Philips, Eindhoven,
The Netherlands) or a mobile (9800 OEC; General Elec-
tric, Milwaukee, Wisc) C-arm fluoroscopy unit. The com-
plete procedure details have also been described previous-
ly.8 Briefly, local anesthesia was used in all patients prior to
obtaining percutaneous femoral arterial access. Aspirin and
clopidogrel were given to all patients 24 hours prior to the
procedure and continued postprocedure until day 30. Sys-
temic intravenous unfractionated heparin sulfate was ad-
ministered prior to crossing the atherosclerotic lesion with
a target activated clot time of 250 to 300 seconds. Cerebral
embolic protection devices were employed in 95% of
cases. All of the stents used were self-expanding nitinol
stents.
Outcome measures
The primary outcome measures in this study were
30-day death, any stroke (major and minor), and myocar-
dial infarction (MI), as well as late death, stroke (major),
and in-stent restenosis. Additionally, a number of cases
were followed for stent fracture. Neurological outcomes
were assessed by independent neurological examinations
using the National Institutes of Health Stroke Scale
(NIHSS) in85% of cases as per the protocols outlined by
the corresponding trial and/or registry. Any death or major
adverse event, defined as MI or stroke, was recorded at 30
days and at 6-month or yearly intervals. At short-term, a
major stroke was defined as any new neurological deficit on
exam and with change on clinical presentation from base-
line discovered beyond the 24-hour postprocedure periodto the 30-day mark and/or increasing the NIHSS by 3
points. Also at short-term, minor stroke was defined as any
new neurological deficit persisting beyond the 24-hour
postoperative period to the 30-daymark without increasing
the NIHSS by 3 points. Alternatively, a transient ischemic
attack was defined as any neurological deficit that only
persisted less than 24 hours. Computed tomography (CT)
or magnetic resonance imaging (MRI) was obtained when
a diagnosis of stroke was entertained for radiographic con-
firmation. Duplex ultrasonography was obtained at 1
month, 6 months, 1 year, and yearly or every 2 years
thereafter. Myocardial infarction was defined by at least two
of the following criteria: typical chest pain lasting 20 min-
utes or more; serum levels of creatine kinase, creatine kinase
MB, or troponin at least twice the upper limit of the normal
range; and new Q wave on at least two adjacent derivations
or predominant R waves in V1 (R wave1 mmS wave in
V1). Patients lost to follow-up were defined as having no
duplex data after a span of 3 years since the last duplex.
Long-term mortality was determined by chart review
and review of the Social Security Death Index. Long-term
stroke and MI were based on clinical history and exam, as
well as chart review. Long-term stroke was defined as any
new neurological deficit with change from baseline within
the vascular territory stented that developed beyond the
30-day mark. Long-term restenosis (ISR) and/or occlu-
sion was screened for by duplex imaging, and those patients
with elevated velocities were directed to angiography. We
followed our institutional algorithm as previously repor-
ted.9 The retreatment options for ISR were balloon angio-
plasty with or without restenting for lesions80% resteno-
sis or medical management if the angiogram revealed less
than an 80% restenosis as defined by NASCET.
A secondary outcome measure followed was long-term
stent fracture. This was monitored by two-view cervical
neck plain film radiography and, in a few instances, CT
imaging. Stent fractures were classified according to a pre-
viously reported nitinol stent fracture standardization doc-
ument.10 Type I are defined as single strut fractures, type II
are multiple strut fractures at different sites, type III are
multiple fractures resulting in transverse linear fracture but
without migration, and type VI are fractures resulting in
transverse linear fracture with migration. All detected stent
fractures were followed up with angiography with the pos-
sibility of restenting or surgical stent removal.
Statistical analysis
All data were collected on Microsoft Excel (Office
2007, Seattle, Wash) and were analyzed on Stata 9.2 (Stata-
Corp, College Station, Tex). All patient charts were re-
viewed independently by the authors (A.A.U. andM.G.T.)
with 99% concordance. Two-sided student t test for con-
tinuous data and a chi-squared or Wilcoxon rank-sum test
for categorical data were used to analyze all subgroups with
significance set at a P value of 0.05. Kaplan-Meier failure
curves are based on the stratified log-rank statistic. A Mar-
tingale-Schoenfeld residuals table was extracted from the
data, and a global test for the proportional hazard was done
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not violated. It was not violated, and therefore, we pro-
ceeded to conduct survival analysis in standard fashion.
Data for patients who were lost to follow-up were censored
at the time of the last contact or bymost recent duplex date.
Adjusted analysis of the primary outcomes was performed
with the use of a Cox-proportional hazards regression
model with multivariate analysis by eight preidentified risk
factors: age, gender, smoking, chronic obstructive pulmo-
nary disease (COPD), hypertension (HTN), prior MI,
prior stroke, and prior ipsilateral or contralateral CEA or
coronary artery bypass graft (CABG). This retrospective
study was initially powered to detect a difference in all-
stroke at long term regardless of stratification. Prior to the
beginning of data collection, it was estimated, given a
power of .80, that approximately 350 cases would be
needed to detect a 1% difference in all-stroke rate at 2 years.
This was based on the National Surgical Quality Improve-
ment Program (NSQIP) data of a combined stroke/death
rate of 3.4% for a population size of 13,622.11 A more
contemporary study examining the outcomes of CEA
among NSQIP private-sector hospitals demonstrated a
combined stroke/death rate of 2.2%.12 We chose the
former study for comparison, since our population includes
patients treated both in the private sector and the VA
healthcare system.
Follow-up period
The mean follow-up is 23.0 months (interquartile
range, 10.9-35.4). Three hundred thirty-five patients were
stented; however, three patients were without any data
prior to 30 days, and 35 patients were without any data
beyond 30 days or hospital discharge. Prior to the start of
data collection, a power analysis demonstrated a require-
ment of approximately 350 cases to determine a 1% all-
stroke rate difference without stratification from an esti-
mated stroke rate in the population of 3.4%. A total of 220
patients had more than 1-year follow-up, and 55 people
were deceased at late follow-up based on chart review and
the Social Security Death Index. Forty-one patients had not
been seen in the previous 3 years, however; 18 of these
patients had greater than 1-year follow-up on record.
RESULTS
Baseline risk factors and stratification groups
Between May 2001 and July 2009, a total of 388 CAS
procedures were performed. Demographic data are shown
in Table I. The average patient age at the time of stenting
was 71 years. The average percent stenosis upon presenta-
tion was 80%. Data were stratified along four primary
variables: symptom status, age greater or less than 80,
exposure to prior radiation, and restenosis after prior ipsi-
lateral carotid endarterectomy. Assuming that stenosis after
radiation or after CEA represents a different set of carotid
lesions than de novo lesions, for purposes of this analysis,
we combined restenosis with radiation patients. There were
only four patients with both CEA and radiation exposurecombined. Only 31% of the patients who were stented had
symptomatic presentations, 13% of patients had prior neck
radiation, and 19% of patients had ipsilateral neck carotid
endarterectomy and were restenotic, while 69% of patients
were de novo lesions. Thirteen percent (n  51) of the
patients were octogenarians, and 31% (n 120) of patients
had either radiation or CEA or both.
The baseline characteristics (for gender, COPD, HTN,
mean age, prior MI, prior stroke, and smoking) when
comparing asymptomatic vs symptomatic, octogenarians vs
nonoctogenarians, and de novo vs restenosis, de novo vs
XRT, or de novo vs XRT/restenosis were similar, with all P
 .5. Less than 10% of data were missing in each baseline
characteristic or stratification group.
Thirty-day outcomes
There were three patients lost to follow-up at 30 days.
Overall 30-day rates of death, stroke, and MI are 0.5%, 1.8%,
and 0.8%, respectively. The 30-day major/minor stroke rates
for analyzed subgroups are statistically significant only for
XRT/restenosis vs de novo lesion, 0% and 2.6% (P .03) but
not for asymptomatic vs symptomatic patients, 1.9% and 1.7%
(P  .9), and age 80 vs 80, 2.0%, and 1.8% (P  .52),
respectively. The combined stroke/death rate was 2.3% (Ta-
ble II).
Long-term outcomes
Death/stroke/MI. The late death rate for the entire
group is 16.8%, with one stent-related death, which oc-
curred at 22 months. It was due to an ischemic stroke at 20
months to the stented side and represents 0.3% of all
stenting. At the mean long-term follow up of 23 months,
there was a 1.7% all-stroke rate; however, when stratified by
groups, the stroke rate was 1.2% for asymptomatic patients
vs 2.8% for symptomatic patients (P  .13) and 2.1% for
Table I. Baseline demographics
Baseline characteristics at time of
stenting Number (percentage)
Average age 70.7
Gender 294 men (76%)
History of COPD 67 (17%)
History of hypertension 346 (89%)
History of hyperlipidemia 274 (71%)
History of tobacco use 196 (51%)
History of diabetes 124 (32%)
History of renal dysfunction 35 (9%)
History of prior myocardial infarction 53 (18%)
History of remote TIA, stroke, or CVA 113 (39%)
History of percutaneous coronary
angioplasty 79 (20%)
History of prior CABG or carotid
endarterectomy 139 (37%)
Average percent stenosis at presentation
by duplex 80%
CABG, Coronary artery bypass graft; COPD, chronic obstructive pulmonary
disease; CVA, cerebrovascular accident; TIA, transient ischemic attack.octogenarians vs 1.6% for nonoctogenarians (P  .60).
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restenotic lesions (P  .03). With regards to MI, the only
significant difference was found in XRT/restenosis vs de
novo lesions at 1.8% vs 5.6%, respectively (P  .05; Table
III). Therefore, lesion type stood out as a single stratifica-
tion group that was significantly different in respect to
stroke and MI; however, our study was not powered to
detect subgroup differences.
Kaplan-Meier curve for long-term mortality and long-
term stroke was constructed. The freedom from mortality
at 12, 24, 36, and 48 months was 93.9%, 87.6%, 82, and
70.3%, respectively (Fig 1 and Table IV). At long-term, the
freedom from all strokes at 12, 24, 36, and 48 months was
99.2%, 97.6%, 96.7%, and 96.7%, respectively (Fig 2 and
Table V).
Restenosis. Over the mean follow-up period of 23
months, 18 stents were identified as suspicious for sig-
nificant (80%) restenosis and/or occlusion as measured
by duplex ultrasound. All 18 patients were asymptom-
atic. Subsequent evaluation with conventional angiogra-
phy demonstrated that five lesions actually had 80%
restenosis as measured by the NASCET methodology
and were, therefore, treated medically. The remaining 13
stents were found to have a 80% restenotic lesion by
angiography, yielding a true restenosis rate of 3.5% (13/
367; Table VI). Of the 13 true restenosis cases; three
Table II. Thirty-day outcomes
Stratification group Stroke
Cumulative 1.8% (7/385)
Symptomatic 1.7% (3/116)
Asymptomatic 1.9% (4/269)
P  .91 (NS)
Octogenarian 2.0% (4/51)
Nonoctogenarian 1.8% (3/334)
P  .52 (NS)
XRT/restenosis 0% (0/120)
De novo 2.6% (7/265)
P  .03*
MI, Myocardial infarction; XRT, external beam neck irradiation.
*Indicates statistical significance.
Table III. Long-term stroke and myocardial infarction
Stratification group Stroke MI
Cumulative 1.7% (6/360) 4.4% (16/360)
Symptomatic 2.8% 7.5%
Asymptomatic 1.1% 3.1%
P  .13 (NS) P  .97 (NS)
Octogenarian 2.1% 2.1%
Nonoctogenarian 1.6% 4.8%
P  .60 (NS) P  .2 (NS)
XRT/restenosis 3.5% 1.8%
De novo 0.8% 5.6%
P  .03* P  .046*
MI, Myocardial infarction; XRT, external beam neck irradiation.
*Indicates statistical significance.cases of complete stent occlusion were detected. In thisgroup, one patient subsequently had a stroke and two
patients remained asymptomatic. Reintervention was
performed in only 10 cases. One of the cases led to
eventual surgical stent removal due to the embolic pro-
tection device catching on the stent and causing intra-
vascular involution. The treatment modalities for these
10 restenosis differed: four underwent balloon angio-
plasty alone, and six underwent angioplasty followed by
re-stenting. Restenosis rates for recurrent stenosis/XRT
Death MI
0.5% (2/385) 0.8% (3/385)
0% (0/116) 0.7% (1/268)
0.7% (2/269) 0.9% (2/116)
P  .17 (NS) P  .54 (NS)
0% (0/51) 2.0% (2/51)
0.5% (2/334) 0.6% (1/333)
P  .29 (NS) P  .85 (NS)
0% (0/120) 1.1% (3/120)
0.7% (2/265) 0% (0/264)
P  .17 (NS) P  .12 (NS)
Fig 1. Freedom from all-cause mortality. Survival curve: over 8
years of follow-up. Dashed line indicates 95% confidence intervals.
Table IV. Life table for all-cause mortality
Interval time
(months)
Total
patients
at start Death
Lost at
time
interval
Percent
survival
95%
confidence
interval
1-12 342 18 97 93.9% 90.4%-96.1%
12-24 227 13 65 87.6% 82.7%-91.2%
24-36 149 8 45 82.0% 75.9%-86.8%
36-48 96 11 38 70.3% 61.6%-77.4%
48-60 47 6 15 60.0% 48.5%-69.1%
60-72 26 0 16 60.0% Wide
72-84 10 2 5 43.8% Wide
84-96 3 0 3 43.8% Widevs de novo lesions are 3.5% and 3.6% (P  .5; Table IV).
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III stent fractures both in de novo lesions, both of which
were closed-cell stents. Kaplan-Meier curves for time to
restenosis and lifetable analysis can be seen in Fig 3 and
Table VII. It is clear that, for the first 3 years, there are
narrow confidence intervals for in-stent restenosis and
ranging from 91.5% or greater at three years. However,
after 3 years, the data become less robust, with wide
confidence intervals.
Fractures. Evaluation for stent fractures was initiated
2 years ago. To date, 73 patients have follow-up plain
radiographic imaging of their carotid stents. The average
follow-up time for stent fracture detection is 30 months
(interquartile range, 12.4-43.6). There were four (5.5%)
total stent fractures. There were two type I stent fractures
Fig 2. Freedom from stroke over 8 years of follow-up. Dashed
line indicates 95% confidence intervals.
Table V. Life table for long-term major stroke
Interval
time
(months)
Total
patients
at start Strokes
Lost
at time
interval
Percent
stroke-free
95%
confidence
interval
1-12 344 2 122 99.2% 97.2%-99.8%
12-24 220 3 85 97.6% 94.3%-99.0%
24-36 132 1 48 96.7% 92.5%-98.6%
36-48 83 0 41 96.7% 92.8%-98.6%
48-60 42 0 18 96.7% 92.8%-98.6%
60-72 24 0 16 96.7% 92.8%-98.6%
72-84 8 0 5 96.7% 92.8%-98.6%
84-96 3 0 3 96.7% 92.8%-98.6%
Table VI. Long-term outcomes restenosis
Outcome measure Mean (number/total)
In-stent restenosis by angiogram 3.5% (13/365)
In-stent restenosis by XRT/restenosis 3.5% P  .5 (NS)In-stent restenosis by de novo 3.6%
XRT, External beam neck irradiation.and two type III fractures.DISCUSSION
Despite its appeal as a minimally invasive alternative to
CEA, CAS has emerged as a highly controversial procedure
with unclear absolute indications. The Stenting and Angio-
plasty with Protection in Patients at High Risk for Endar-
terectomy (SAPPHIRE) trial is the only randomized con-
trolled trial comparing CEA vs CAS that has reported data
in favor of CAS. Despite its flaws, SAPPHIRE demon-
strated that the 30-day combined MI, stroke, and death
cumulative incidence for CAS vs CEA was 4.8% in the CAS
arm vs 9.8% in the CEA arm (P  .09).13 Results at the
3-year follow-up were also in favor of endovascular treat-
ment, with CAS compositeMI, stroke, and death of 24.6 vs
26.9 for CEA (P  .71).14 Alternatively, The Endarterec-
tomy vs Angioplasty in Patients with Severe Symptomatic
Carotid Stenosis (EVA-3S), a noninferior randomized con-
trol trial comparing CAS and CEA showed the 30-day
combined stroke/death for CAS vs CEA was 9.6% vs 3.9%
(P  .01).15 More recently, EVA-3S published 4-year
results, which favored CEA with the cumulative probability
of periprocedural and nonprocedural ipsilateral stroke/
death of 11.1% for CAS vs 6.2% for CEA (P  .03).16
In this report, we have demonstrated a combined 30-
day stroke/death rate of 2.3%, which is not statistically
Fig 3. In-stent restenosis freedom rate over 8 years of follow-up.
Dashed line indicates 95% confidence intervals.
Table VII. Life table for in-stent restenosis by year
Interval
time
(months)
Total
at
start
Number
of
restenosis
Lost at
the end
of cycle
Percent
patent
at cycle
95%
confidence
interval
1-12 358 6 112 98.0% 95.6%-99.1%
12-24 240 3 105 96.5% 93.2%-98.2%
24-36 132 1 48 95.5% 91.5%-97.7%
36-48 83 2 41 92.5% 85.5%-96.2%
48-60 40 1 19 89.5% 78.8%-95.0%
60-72 20 0 15 89.5% 78.8%-95.0%
72-84 5 0 3 89.5% 78.8%-95.0%
84-96 2 0 2 89.5% 74.8%-95.0%significantly different from our institutional 30-day stroke/
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contradistinction to CAS, only a minority of our CEA
patients had independent postoperative neurologic exami-
nations. Several factors likely impacted our favorable CAS
results: 1) selection bias–patients with unfavorable anatomy
were treated with CEA; 2) a preponderance of asymptom-
atic patients in the study cohort; 3) a preponderance of men
in the study cohort; 4) a minority of octogenarians in the
study cohort; and 5) significant endovascular skills of the
primary operators. Some of these items have been recently
identified as important aspects to the outcomes of CAS as
identified in the Society for Vascular Surgery Vascular
Registry.17 Although there are insufficient data to make
confident conclusions about some of the subset of patients,
it is interesting to note that the 30-day stroke rate was
higher for de novo lesions as compared with restenotic
lesions and those lesions previously subjected to external
beam radiation. Again, insufficient data also likely impacted
our findings of nearly equivalent stroke outcomes among
asymptomatic and symptomatic patients, as well as among
octogenarians and nonoctogenarians. Certainly, the latter
cohort has been shownmost notably in the lead-in phase of
the CREST study to be an important risk factor in early
CAS outcomes.18
A limited number of institutional reviews with long-
term follow-up have also been reported. Among the early
studies on CAS, Roubin et al reported an incidence at
3-years follow-up for fatal and nonfatal stroke of 3.2% after
CAS. Furthermore, they demonstrated a 3-year freedom
from ipsilateral or fatal stroke of 92%  1%.19 Lin et al
reviewed 380 cases of CAS and showed, at median
follow-up of 29 months, a 12, 24, 36, and 48 month
stroke-free rate of 97%, 91%, 89%, and 85%, respectively.20
The largest known long-term retrospective study from
Europe by de Donato et al reviewed 3179 CAS performed
at four centers with outcomes at 5 years comparable to
conventional surgery. They found, at 5 years, freedom from
mortality, stroke-related death, ipsilateral fatal/major
stroke, and any stroke rates were 82%, 93.5%, 93.3%, and
91.9%, respectively.21 Our long-term freedom from stroke
and mortality are comparable to the aforementioned re-
ports. Additionally, the cumulative all-cause mortality rate
demonstrated in SAPPHIRE at 3 years was reported at
18.6%, similar to the 16.8% rate we currently report over a
mean follow-up of 23 months.
In-stent restenosis has been identified as one of the
primary long-term failings of CAS. Restenosis of clinical
relevance (80%) has been reported between 2% and
13%.22DeDonato et al found freedom from restenosis at 1,
3, and 5 years was 98.4%, 96.1%, and 94%, respectively.
Additionally, they showed that stent characteristics (mate-
rial/design/free-cell area) were not significantly associated
with time to in-stent restenosis or time to reintervention.21
In this report, we demonstrate a low in-stent restenosis rate
of 3.5%. Duplex criteria are an excellent screening tool in
determining ISR; however, angiography remains the defin-
itive standard for ISR detection. Defining ISR is also an
important consideration. While some groups define ISR as50% or any lesion requiring subsequent interventional
treatment, we define it as 80% stenosis as measured by
NASCET. We found that out of 18 stents on duplex with
possible ISR did not have ISR on angiography. We feel it is
practical to set 1- to 2-year cycles to screen for ISR based on
the increase in failure rate at 3 to 5 years. There has been
some speculation that CAS of recurrent stenotic lesions
may be associated with higher rates of ISR secondary to
stimulation of an already activated intimal hyperplastic le-
sion. We have previously reported no significant difference
in ISR between these groups.23
Likewise, carotid stent fracture is not uncommon and
has been associated with the presence of calcification in the
internal carotid artery. Varcoe et al found a stent fracture
prevalence of 2.2% in 48 carotid stents placed in 43 pa-
tients.24 They reported that a calcified artery is eight times
more likely to have a fracture. We started evaluating our
patients for stent fractures 2 years ago with two-view cervi-
cal radiographs after identifying a type III fracture with
restenosis.25 The location of CAS exposes stents to stretch-
ing and axial forces from the neck leading to an increased
propensity for stent fractures. Given the 5.5% fracture
detection at 30-month follow-up, we feel that annual two-
view cervical radiography should be part of the routine
surveillance for CAS. Management of fractures is depen-
dent on the clinical and radiographic findings but range
from medical management to surgical excision.
There are some obvious limitations to the current
study. First, the nature of a retrospective review leads to
strong selection bias in CAS patients. Second, our study
was powered to detect the all-stroke rate without a sub-
group analysis. Despite the fact that some differences were
seen between certain subgroups (ie, de novo lesions) and
not among others (ie, octogenarians and preprocedure
symptoms status) likely illustrates a type 2 statistical error.
Last, patients lost to follow-up over the years hinder our
ability to provide a more comprehensive analysis of late
outcomes.
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